About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 63431 record(s)
Req # A-2021-002142
Adverse Drug Reactions (ADRs) for ZOPICLONE, BUDESONIDE, QUADRIVALENT INFLUENZA VACCINE. Report numbers: E2B_04821402, E2B_04819777, E2B_04546577, 000974506.Organization: Health Canada
June 2022
Req # A-2021-002153
Adverse Drug Reactions (ADRs) for ALEMTUZUMAB, ALIROCUMAB, CABAZITAXEL, ENOXAPARIN SODIUM, FUROSEMIDE. Report numbers: 000967750, E2B_04898115, 000975008, E2B_04904547, E2B_04685448, 000976602, 000975238, E2B_04647826, E2B_04632578.Organization: Health Canada
June 2022
Req # A-2022-000001
Adverse Drug Reactions (ADRs) for METFORMIN, METFORMIN HYDROCHLORIDE, METOLAZONE, RANITIDINE. Report numbers: E2B_04799227, E2B_04906981, E2B_04913738, E2B_04888052, E2B_04781178, 000975040, E2B_04811723, E2B_04799802, E2B_04921453, E2B_04925972.Organization: Health Canada
June 2022
Req # A-2022-000004
Adverse Drug Reactions (ADRs) for METFORMIN, METFORMIN HYDROCHLORIDE, METOLAZONE, RANITIDINE. Report numbers: 000977292, E2B_03623086, E2B_04657718, E2B_04724520, 000973481, E2B_04683448, E2B_04683292.Organization: Health Canada
June 2022
Req # A-2022-000005
Adverse Drug Reactions (ADRs) for RANITIDINE HYDROCHLORIDE, ZOPICLONE. Report numbers: E2B_04938746, E2B_04772196, E2B_04821402, E2B_04675804, E2B_04793351.Organization: Health Canada
June 2022
Req # A-2022-000010
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-102424-617, Digital Transformation Branch Structure.Organization: Health Canada
June 2022
Req # A-2022-000013
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-101702-725.Organization: Health Canada
June 2022
Req # A-2022-000028
Adverse Drug Reactions (ADRs). Report numbers: E2B_04704010, E2B_04718385, 970537, 970543, 971165, 971396, E2B_04773942, E2B_04774155, E2B_04751076, E2B_04763945.Organization: Health Canada
June 2022
Req # A-2022-000029
Adverse Drug Reactions (ADRs). Report numbers: 977404, E2B_04787155, E2B_04795026, E2B_04798528, 971605, 972249, 971392, 973210, 973216, E2B_04801281.Organization: Health Canada
June 2022
Req # A-2022-000053
Adverse Drug Reaction (ADR) for Duloxetine. Report number: E2B_03524643.Organization: Health Canada
June 2022